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Is it Time to Lower the Bar?*
Linda Pape, MD, Samuel Joffe, MD
Worcester, Massachusetts
Aortic valve surgery accounts for the majority of heart valve
operations in the United States and is usually performed
according to official guidelines of the American College of
Cardiology and American Heart Association (1). It has
been long established that once aortic stenosis (AS) be-
comes severe, the majority of patients will develop symp-
toms (angina, syncope, congestive heart failure) within 5
years and thus require surgery (2,3). Without surgery their
prognosis is dismal (4). But what about the asymptomatic
patient? Should surgery be performed early to pre-empt
adverse remodeling associated with AS and other comor-
bidities? Or should it be delayed to favor the use of a
bioprosthetic, rather than mechanical valve, and possibly to
avoid a subsequent repeat procedure? In the present study,
Beach et al. argue for early evaluation of asymptomatic
patients with severe AS and coronary artery disease (CAD)
risk factors, followed by surgical aortic valve replacement
(AVR) and revascularization prior to the development of
ischemic myocardial damage if risk factors are present.
See page 837
Although aortic valve replacement is the only solution for
the mechanical problem of severe stenosis, the disease of
degenerative AS must be viewed as more than a simple
mechanical problem. As a disease of the older patient—the
average patient undergoing AVR is in their seventh or
eighth decade—AS does not often occur in isolation. It is
frequently accompanied by comorbidities such as hyperten-
sion, CAD, and peripheral vascular disease, all of which
influence the course of the disease.
Many AS patients undergo coronary artery bypass graft
surgery (CABG) at the time of AVR and have a higher
operative mortality than those having AVR alone (5). Beach
et al. examined the survival implications of CAD in patients
with severe AS (6). They studied 3,923 patients all of whom
received a single type of bovine AVR for severe AS; 1,637
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Division of Cardiovascular Medicine, University of Massachusetts
Memorial Medical Center, Worcester, Massachusetts. Both authors have reported
that they have no relationships relevant to the contents of this paper to disclose.isolated AS patients underwent AVR alone and 2,286 with
severe AS and CAD underwent AVR and CABG. Patients
were followed at 2 and 5 years. Using propensity scores,
isolated AS patients were matched to ASCAD patients
(total 2,164 matched patients). Survival analysis was per-
formed on all. Numerous sophisticated and novel statistical
techniques and models were used to identify unique risk
factors between the 2 groups (isolated AS and ASCAD)
and to study survival.
Not surprisingly, the AS patients on the whole were
younger and enjoyed better outcomes than the ASCAD
patients who were older with more comorbidities. Patients
with isolated AS had the best outcomes, patients with
ASCAD without evidence of ischemic myocardial dam-
age had an intermediate prognosis, equivalent to patients
with isolated AS with similar comorbidities, while patients
with ASCAD with ischemic damage and multiple comor-
bidities had the worst outcomes.
A key finding of this study is that the survival curves for
the propensity matched AS and ASCAD patients were
similar. Roberts recently showed equal early and late mor-
tality in 871 propensity matched patients undergoing AVR
with and without CABG (7). De Waard et al. showed by
multivariate analysis that concomitant CABG was not
independently associated with increased mortality (8). Thus,
it is the patient characteristics and comorbidities, not the
procedure, that determine outcome.
AS patients were adversely affected by left ventricular hy-
pertrophy (LVH) and diastolic dysfunction. In the matched
group, the adverse effect of LVH in AS-only patients was
equivalent to the effect of CAD in ASCAD patients. A
number of investigators have asked if outcomes might be
improved by earlier valve replacement before a significant
increase in left ventricular (LV) mass index occurs (9–12).
Beach et al. add their voices to this consideration for pre-
emptive surgery but fall short of suggesting specifics. Fuster et
al. in 2003 called for a randomized trial, but to date none has
been done (11).
ASCAD patients’ mortality in this study was associated
with the effects of prior myocardial damage. Beach et al.
therefore recommend that early diagnosis of CAD and, by
implication, revascularization, may prevent ischemic dam-
age in AS patients. Yet a large body of literature does not
support preemptive revascularization for asymptomatic cor-
onary disease. Such a strategy needs to be proven before
surgery can be recommended in the asymptomatic patient.
The unmatched AVRCAD group, the older, sicker
patients with many comorbidities and worse LV function
had the poorest survival. With the advent of transcatheter
strategies for valve implantation one already sees a trend
toward a “softening” of indications for AVR, though guide-
lines do not yet address transcatheter approaches in asymp-
tomatic patients.
The elusive goal for decades has been to identify factors,
which, if identified early, would improve surgical outcomes.
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and its consequences: LVH, myocardial fibrosis, and LV
diastolic dysfunction (2,3,10–12). LV systolic dysfunction is
often more subtle; it can be difficult to differentiate myo-
cardial contractile failure from so-called afterload mismatch.
Factors that correlate with poor prognosis include the
degree of valve calcium, high gradient, LV mass index, and
concentric remodeling (10–14). More recently the degree of
LV longitudinal shortening, B-type natriuretic peptide lev-
els, flow/gradient ratios, and myocardial fibrosis using mag-
netic resonance imaging have all been studied as prognostic
indicators with the hope of better defining and refining
surgical indications (14–19). Many physicians have errone-
ously equated normal left ventricular ejection fraction
(LVEF) with normal output/flow. Hachicha et al. brought
to attention the fact that patients with low gradients due to
low flow (despite preserved LVEF) may not, because of
their low gradients, be recognized as having severe AS (20).
Pibarot and Dumesnil emphasized the interrelation between
valvular, ventricular, and arterial variables in newer ap-
proaches to assessing disease severity (21).
The fact that LVH and diastolic dysfunction adversely
influence outcome in isolated AS does not in itself support
performing AVR prior to symptom onset, as Beach et al.
suggest. A commonly held idea is that if LVH regresses,
function will improve. But LVH alone does not account for
diastolic dysfunction, fibrosis also plays a significant role
(19). Myocardial fibrosis causes decreased LV longitudinal
shortening, which in turn predicts lack of functional im-
provement. Weidemann, using intraoperative myocardial
biopsy and pre- and post-operative CMR, showed that
fibrosis did not resolve after AVR (18). Of 21 patients with
severe fibrosis, 4 died during follow-up; none of the 37 with
no or mild fibrosis did. Using CMR, Dweck et al. showed
that the pattern of LV remodeling and degree of LVH
varied considerably and did not closely correlate with the
severity of stenosis (22). These studies among many others
suggest we still have a lot to learn about this disease. At
what stage are changes irreversible? What interplay of
factors is associated with irreversibility? And what are those
factors?
The guidelines are changing. LV systolic dysfunction
with EF 50% portends a poor prognosis and is now a
Class I indication in severe AS patients even if asymptom-
atic. Perhaps longitudinal shortening, more reflective of the
effects of myocardial fibrosis, will one day be included as a
better indication than LVEF of myocardial dysfunction.
The growing practice of exercise testing to uncover symp-
toms is reflected in the new European Society of Cardiol-
ogy/European Association for Cardio-Thoracic Surgery
guidelines; with a Class I indication, “AVR is indicated in
asymptomatic patients with severe AS and abnormal exer-
cise test. . .” (still a Class IIb American College of Cardi-
ology/American Heart Association 2008 guideline indica-
tion). The European Society of Cardiology/European
Association for Cardio-Thoracic Surgery guidelines includeas Class IIa asymptomatic patients with normal EF with
peak transvalvular velocity 5.5 m/s or severe valve calcium
nd peak valve velocity progression of0.3 m/s per year (5).
The large well-conducted study of Beach et al. provides a
ealth of information on a carefully characterized group of
atients undergoing AVR with and without CABG and
mphasizes the role of risk factors and comorbidities in
etermining surgical and longer-term survival among the
road range of AS patients. It helps us focus on the as yet
nanswered question: Which high-risk asymptomatic AS
atients will benefit from surgery? Will earlier intervention
ake a difference? Only a randomized clinical trial will
nswer these questions. In the meantime, we must apply our
nowledge of risk factors for morbidity and mortality, of
urgical outcomes, of the systemic nature of the disease, and
mportantly knowledge of our patients themselves in order
o make the best decisions. They look to us for guidance,
ot guidelines.
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